The content on this site is intended for healthcare professionals only
Screening and specialist nurses central to patient care
Tivantinib first drug to have overall survival benefit as second-line hepatocellular carcinoma treatment
Adjuvant cetuximab disappoints again in mCRC
Young Voices United against CRC
Advances in radiotherapy for rectal cancer
Important to support young medical oncologists’ research
Role of family history and genetic testing in diagnosis
Effects of panitumumab against oesophageal-gastro cancer and carcinomas
Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies
President's overview of ASCO 2012
Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies
Continuing bevacizumab with second-line chemotherapy for colorectal cancer
